BBIO Infigratinib NDA: Achondroplasia Sleep and Ear Data

BridgeBio (BBIO) has submitted its New Drug Application (NDA) for oral infigratinib in achondroplasia and presented new data showing the drug does more than add height. Shares closed at $76.08.

Infigratinib is a once-daily pill that blocks FGFR3, the receptor whose overactivity causes achondroplasia, the most common form of disproportionate short stature. Overactive FGFR3 signaling throttles the growth plate; dialing that signal down lets bones lengthen normally. It would be the first oral treatment for the condition, competing against BioMarin’s injectable Voxzogo (vosoritide), a C-type natriuretic peptide analog that works around FGFR3 rather than on it. The convenience gap is the whole thesis: Voxzogo is a daily shot, infigratinib a pill. BridgeBio, which is partnered with Kyowa Kirin on the program, expects a U.S. launch in mid-2027 and plans an EU filing in the fourth quarter of 2026.

The new data, presented at the European Society for Paediatric Endocrinology (ESPE) meeting in Marseille, went beyond the growth chart. In PROPEL 3, the registrational Phase 3 trial, the apnea-hypopnea index rose 10.4% over 52 weeks in treated children versus 49.2% on placebo. In children under 8, the measure was unchanged on infigratinib versus a 63.2% worsening on placebo. The annualized rate of ear infections (otitis media) was 38% lower on infigratinib, and 47% lower in the under-8 group.

Three-year follow-up showed the effect holds up. Height Z-score improved 0.92 standard deviations and the upper-to-lower body segment ratio fell 0.15, with no new safety signals. The results published in the New England Journal of Medicine showed a 2.10 cm/year improvement in annualized height velocity versus placebo (p<0.0001) and the first statistically significant arm-span gain of any achondroplasia trial, at 0.37 standard deviations.

Achondroplasia affects about 55,000 people in the U.S. and EU, including up to 10,000 children with open growth plates, and it brings complications beyond short stature, including obstructive sleep apnea, middle ear dysfunction, and spinal stenosis, which is what the ESPE data addresses. Infigratinib holds Breakthrough Therapy, Orphan, Fast Track, and Rare Pediatric Disease designations and could earn a Priority Review Voucher if approved.

The risk is timing and evidence quality. The sleep and ear endpoints are exploratory, so the FDA will lean hardest on the growth data, and a decision is still months away. Voxzogo is already approved and entrenched, so BridgeBio must convince physicians that oral convenience and broader benefits justify a switch. BridgeBio is also advancing infigratinib in hypochondroplasia, racing BioMarin’s expanding Voxzogo (vosoritide) franchise. Watch the EU filing in Q4 and the mid-2027 launch target.

What It Means for the Trade

The NDA filing converts infigratinib from a pipeline line-item into a dated regulatory catalyst, and the ESPE data is BridgeBio’s attempt to win the launch before the label arrives. Here is why the sleep apnea and otitis media data matter more than their exploratory status suggests: the achondroplasia market is not really a height market, it is a complications market. Parents and pediatricians tolerate daily injections for Voxzogo because short stature is visible and measurable, but the medical burden that drives payer coverage and long-term outcomes is foramen magnum stenosis, sleep apnea, chronic ear infections, and spinal stenosis. The PROPEL 3 data — apnea-hypopnea index worsening of 10.4% on drug versus 49.2% on placebo, ear infections down 38% overall and 47% in under-8s — gives the sales force a story Voxzogo’s label cannot directly counter: infigratinib addresses the FGFR3 overactivity that drives the complications themselves, not just the growth plate.

The commercial setup is a classic convenience-versus-incumbent fight. Voxzogo is a daily subcutaneous injection with years of real-world experience, physician familiarity, and an established reimbursement pathway; infigratinib is a once-daily pill with a mechanism that works upstream of where vosoritide acts. Oral dosing in a pediatric population is a genuine differentiator — daily injections are the number-one adherence complaint in this class — but switching costs in rare pediatric disease are high, because physicians don’t switch stable children lightly. The realistic bull case is not rapid conversion but new-patient capture at diagnosis, where the pill-versus-shot choice is made without a switch decision. The under-8 subgroup data is therefore strategically important: newly diagnosed patients are mostly young, and that is where the complication-prevention signal is strongest.

Mechanism and Competitive Context

The mechanism contrast defines the fight. Achondroplasia is FGFR3 gain-of-function disease: the overactive receptor suppresses chondrocyte proliferation in the growth plate. Infigratinib blocks the receptor’s kinase activity directly at the source; vosoritide sidesteps FGFR3 entirely by stimulating natriuretic peptide pathways downstream that counteract the growth suppression. Working at the source is the mechanistic argument behind the complications data — FGFR3 signaling is not confined to the growth plate, it is expressed in bone, ear, and craniofacial development, which is why an FGFR3 inhibitor might plausibly help otitis media and apnea while a growth-plate work-around might not. The NEJM-published growth data (2.10 cm/year height velocity gain, p<0.0001, and the first statistically significant arm-span gain at 0.37 SD) anchors the registrational case, and the three-year durability (height Z-score +0.92 SD, no new safety signals) answers the chronic-dosing question.

The regulatory calendar is the immediate trade. With the NDA filed, mid-2027 launch target, and an EU filing in Q4 2026, the catalyst ladder is dated — and the Priority Review Voucher possibility adds a wrinkle: Rare Pediatric Disease vouchers trade for real money if BridgeBio would rather monetize than launch, though the infigratinib indication is clearly a launch the company wants to own.

Risks and What Could Go Wrong

1. The FDA weights the exploratory complications data at zero and the label reads as a growth drug only — the differentiated launch story collapses into “cheaper oral alternative,” a price-war position against an entrenched BioMarin.
2. Voxzogo’s franchise momentum — new indications, label expansions, dosing improvements — closes the convenience gap before infigratinib launches.
3. FGFR inhibitor safety in children: infigratinib was originally an oncology asset, and long-term pediatric exposure to an FGFR3 inhibitor raises retinal, renal, and growth-plate questions that three years of follow-up may not fully answer.
4. BioMarin’s hypochondroplasia expansion: the two companies are racing in adjacent skeletal dysplasias, and whoever reads out first sets the pediatric endocrinology prescribing pattern for both.

Position read: BBIO holders are getting a second commercial franchise candidate on top of Attruby, and the filing makes it dated. The trade is to watch the FDA’s review discipline — if the complications data gets even a whisper of label presence, the launch math changes materially; if not, this becomes a convenience play in an incumbent’s market.

Source: BridgeBio ESPE / NDA press release